AU Patent

AU2023407370A1 — Bezuclastinib formulations

Assigned to Cogent Biosciences Inc · Expires 2025-07-03 · 1y expired

What this patent protects

The disclosure relates to formulations of bezuclastinib, methods of making such formulations, and methods of using such formulations in the treatment of conditions, diseases, or disorders that would benefit from modulation of c-Kit protein kinases and /or mutant c-kit protein kin…

USPTO Abstract

The disclosure relates to formulations of bezuclastinib, methods of making such formulations, and methods of using such formulations in the treatment of conditions, diseases, or disorders that would benefit from modulation of c-Kit protein kinases and /or mutant c-kit protein kinases.

Drugs covered by this patent

Patent Metadata

Patent number
AU2023407370A1
Jurisdiction
AU
Classification
—
Expires
2025-07-03
Drug substance claim
No
Drug product claim
No
Assignee
Cogent Biosciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.